Epidermal Growth Factor Receptors in Brain and Breast Tumors
Author Information
Author(s): R.A. Hawkins, E. Killen, I.R. Whittle, W.J.L. Jack, U. Chetty, R.J. Prescott
Primary Institution: University Department of Surgery, Royal Infirmary of Edinburgh
Hypothesis
What is the clinical significance of epidermal growth factor receptors (EGFR) in intracranial and breast tumors?
Conclusion
EGFR activity is present in a significant proportion of breast and brain tumors, but it has little prognostic significance.
Supporting Evidence
- EGFR was present in 43% of 131 breast tumors and 75% of 55 primary cerebral tumors.
- EGFR activity showed a strong inverse correlation with estrogen receptors in breast tumors.
- High levels of EGFR activity were associated with glioblastoma multiforme.
Takeaway
This study looked at how a certain protein, called EGFR, is found in brain and breast tumors. They found it in many tumors, but it didn't help doctors predict how well patients would do.
Methodology
The study measured EGFR activity in tumor samples from patients using a specific binding assay.
Limitations
The study population may not represent the full spectrum of breast cancers, and the assay may not have been sensitive enough for small samples.
Participant Demographics
Patients ranged from 2 to 84 years old, with a mix of breast and brain tumor types.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website